Catherine Dargan

Catherine J. Dargan

Download V-card

Covington & Burling LLP
One CityCenter
850 Tenth Street, NW
Washington, DC 20001-4956
Tel: +1 202 662 5567



  • Harvard Law School, J.D., 1994
    • cum laude
  • Stanford University, A.B., 1991
    • with honors

Judicial Clerkship

  • Hon. Matthew J. Perry, U.S. District Court, District of South Carolina, 1994-1995

Bar Admissions

  • California
  • District of Columbia

From sales of emerging venture-backed companies to multi-billion dollar acquisitions, Catherine Dargan has advised numerous companies on their important strategic transactions for over 20 years. Ms. Dargan has broad experience in mergers and acquisitions, both public and private, and partnering arrangements. Ms. Dargan is Chambers-rated in Corporate/M&A, serves on the editorial board of M&A360, and was designated a “Life Science Star” and was recently named “Best in M&A” by LMG Euromoney and among The National Law Journal’s "Outstanding Women Lawyers." She co-leads Covington’s Mergers & Acquisitions practice and is a member of the firm's Management Committee. According to the latest edition of Legal 500 US (2015), Ms. Dargan “is ‘excellent, pragmatic, personable and dedicated’.

Representative Matters

  • AstraZeneca in its:
    • $600 million acquisition of Actavis’ branded respiratory business in the U.S. and Canada;    
    • $1.26 billion acquisition of Ardea Biosciences (NASDAQ: RDEA);
    • up to $4.3 billion acquisition of Bristol-Myers Squibb's interests in the companies’ diabetes alliance in initial consideration and regulatory, launch and sales-related payments;
    • approximately $3.5 billion strategic diabetes alliance with Bristol-Myers Squibb in connection with BMS’s acquisition of Amylin Pharmaceuticals, including assistance in structuring agreements for the acquisition and operation of Amylin’s diabetes business by AZ and BMS;
    • acquisition of AlphaCore Pharma by MedImmune, AstraZeneca's biologic arm; and
    • $325 million divestiture of assets relating to Myalept.

Honors and Rankings

  • The National Law Journal, "Outstanding Women Lawyers" (2015)   
  • Named as "Best in Mergers & Acquisitions" by Euromoney Legal Media Group, Americas Women in Business Law Awards (2014)
  • Chambers USA, Corporate/M&A & Private Equity (2014-2015)
  • National Law Journal, D.C. Corporate Deal Makers (2013)
  • LMG Life Sciences, “Life Science Star” (2012-2015)
  • Legal 500 US
    • Leading Lawyer in M&A: Large deals ($1B-$5B) (2014)
    • M&A: Large deals ($1B-$5B) (2012-2015)
    • Healthcare: Life Sciences (2013-2014)
    • Media, Technology and Telecoms (2014)

Pro Bono

  • Represented a non-profit, non-partisan policy organization dedicated to engaging young adults in the political process.
  • Advised a non-profit in various consulting and services arrangements.

Memberships and Affiliations

  • Law360, Mergers & Acquisitions Editorial Advisory Board (2012-present)

Publications and Speeches

  • "Life Sciences Acquisitions and Divestitures: Special Considerations," Practising Law Institute (4/9/2015)
  • "Life Sciences Acquisitions and Divestitures," Faculty Member, Practising Law Institute (2015)
  • "Drafting Corporate Agreements — Letters of Intent, Confidentiality and Standstill Agreements," Faculty Member, Practising Law Institute (2011, 2012 and 2014)
Print PDF Word Version Print this page

Inside Medical Devices Blog